• +1-646-491-9876
    • +91-20-67278686

    Search

    Thyroid Cancer-Pipeline Review H2 2017

    Thyroid Cancer-Pipeline Review H2 2017

    • Report Code ID: RW00011060439
    • Category Life Sciences
    • No. of Pages 490
    • Publication Month Sep-17
    • Publisher Name Global Markets Direct
    Thyroid Cancer-Pipeline Review, H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Thyroid Cancer-Pipeline Review, H2 2017, provides an overview of the Thyroid Cancer (Oncology) pipeline landscape.

    Thyroid cancer is a cancer that starts in the thyroid gland. Symptoms include lump that can be felt through the skin on neck, difficulty swallowing, pain in neck and throat and swollen lymph nodes in neck. Predisposing factors include female, high levels of radiation and inherited genetic syndromes. Treatment includes surgery and thyroid hormone therapy.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Thyroid Cancer-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Thyroid Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Thyroid Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Thyroid Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 33, 28, 1, 11 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 3 and 5 molecules, respectively.

    Thyroid Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The pipeline guide provides a snapshot of the global therapeutic landscape of Thyroid Cancer (Oncology).
    -The pipeline guide reviews pipeline therapeutics for Thyroid Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    -The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    -The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    -The pipeline guide reviews key companies involved in Thyroid Cancer (Oncology) therapeutics and enlists all their major and minor projects.
    -The pipeline guide evaluates Thyroid Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    -The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    -The pipeline guide reviews latest news related to pipeline therapeutics for Thyroid Cancer (Oncology)

    Reasons to buy

    -Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    -Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    -Find and recognize significant and varied types of therapeutics under development for Thyroid Cancer (Oncology).
    -Classify potential new clients or partners in the target demographic.
    -Develop tactical initiatives by understanding the focus areas of leading companies.
    -Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    -Formulate corrective measures for pipeline projects by understanding Thyroid Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    -Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    Introduction 5
    Thyroid Cancer-Overview 6
    Thyroid Cancer-Therapeutics Development 7
    Thyroid Cancer-Therapeutics Assessment 20
    Thyroid Cancer-Companies Involved in Therapeutics Development 32
    Thyroid Cancer-Drug Profiles 55
    Thyroid Cancer-Dormant Projects 465
    Thyroid Cancer-Discontinued Products 467
    Thyroid Cancer-Product Development Milestones 468
    Appendix 480

    List of Tables
    Number of Products under Development for Thyroid Cancer, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017 (Contd..1), H2 2017
    Products under Development by Companies, H2 2017 (Contd..2), H2 2017
    Products under Development by Companies, H2 2017 (Contd..3), H2 2017
    Products under Development by Companies, H2 2017 (Contd..4), H2 2017
    Products under Development by Companies, H2 2017 (Contd..5), H2 2017
    Products under Development by Universities/Institutes, H2 2017
    Number of Products by Stage and Target, H2 2017
    Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
    Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Thyroid Cancer-Pipeline by AbbVie Inc, H2 2017
    Thyroid Cancer-Pipeline by Advenchen Laboratories LLC, H2 2017
    Thyroid Cancer-Pipeline by AstraZeneca Plc, H2 2017
    Thyroid Cancer-Pipeline by Bayer AG, H2 2017
    Thyroid Cancer-Pipeline by BeiGene Ltd, H2 2017
    Thyroid Cancer-Pipeline by Biovista Inc, H2 2017
    Thyroid Cancer-Pipeline by Blueprint Medicines Corp, H2 2017
    Thyroid Cancer-Pipeline by Boehringer Ingelheim GmbH, H2 2017
    Thyroid Cancer-Pipeline by Bristol-Myers Squibb Company, H2 2017
    Thyroid Cancer-Pipeline by Celldex Therapeutics Inc, H2 2017
    Thyroid Cancer-Pipeline by Centrose LLC, H2 2017
    Thyroid Cancer-Pipeline by Curis Inc, H2 2017
    Thyroid Cancer-Pipeline by Cytori Therapeutics Inc, H2 2017
    Thyroid Cancer-Pipeline by Daiichi Sankyo Company Ltd, H2 2017
    Thyroid Cancer-Pipeline by Ecrins Therapeutics SAS, H2 2017
    Thyroid Cancer-Pipeline by Eisai Co Ltd, H2 2017
    Thyroid Cancer-Pipeline by Ensol Biosciences Inc, H2 2017
    Thyroid Cancer-Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
    Thyroid Cancer-Pipeline by Genelux Corp, H2 2017
    Thyroid Cancer-Pipeline by Genmab A/S, H2 2017
    Thyroid Cancer-Pipeline by GlaxoSmithKline Plc, H2 2017
    Thyroid Cancer-Pipeline by Gradalis Inc, H2 2017
    Thyroid Cancer-Pipeline by Hutchison MediPharma Ltd, H2 2017
    Thyroid Cancer-Pipeline by Ignyta Inc, H2 2017
    Thyroid Cancer-Pipeline by Immune Pharmaceuticals Inc, H2 2017
    Thyroid Cancer-Pipeline by Immunomedics Inc, H2 2017
    Thyroid Cancer-Pipeline by Johnson & Johnson, H2 2017
    Thyroid Cancer-Pipeline by Konruns Pharmaceutical Co Ltd, H2 2017
    Thyroid Cancer-Pipeline by Loxo Oncology Inc, H2 2017
    Thyroid Cancer-Pipeline by MacroGenics Inc, H2 2017
    Thyroid Cancer-Pipeline by MaxiVAX SA, H2 2017
    Thyroid Cancer-Pipeline by MedImmune LLC, H2 2017
    Thyroid Cancer-Pipeline by Merck & Co Inc, H2 2017
    Thyroid Cancer-Pipeline by Merck KGaA, H2 2017
    Thyroid Cancer-Pipeline by Millennium Pharmaceuticals Inc, H2 2017
    Thyroid Cancer-Pipeline by Nerviano Medical Sciences Srl, H2 2017
    Thyroid Cancer-Pipeline by Novartis AG, H2 2017
    Thyroid Cancer-Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
    Thyroid Cancer-Pipeline by Pfizer Inc, H2 2017
    Thyroid Cancer-Pipeline by Plexxikon Inc, H2 2017
    Thyroid Cancer-Pipeline by Rodos BioTarget GmbH, H2 2017
    Thyroid Cancer-Pipeline by Synactix Pharmaceuticals Inc, H2 2017
    Thyroid Cancer-Pipeline by Tarveda Therapeutics Inc, H2 2017
    Thyroid Cancer-Pipeline by Vaccinex Inc, H2 2017
    Thyroid Cancer-Pipeline by Vascular Biogenics Ltd, H2 2017
    Thyroid Cancer-Pipeline by XSpray Microparticles AB, H2 2017
    Thyroid Cancer-Dormant Projects, H2 2017
    Thyroid Cancer-Dormant Projects, H2 2017 (Contd..1), H2 2017
    Thyroid Cancer-Discontinued Products, H2 2017

    List of Figures
    Number of Products under Development for Thyroid Cancer, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Number of Products by Top 10 Targets, H2 2017
    Number of Products by Stage and Top 10 Targets, H2 2017
    Number of Products by Top 10 Mechanism of Actions, H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
    Number of Products by Routes of Administration, H2 2017
    Number of Products by Stage and Routes of Administration, H2 2017
    Number of Products by Top 10 Molecule Types, H2 2017
    Number of Products by Stage and Top 10 Molecule Types, H2 2017
    AbbVie Inc
    Advenchen Laboratories LLC
    AstraZeneca Plc
    Bayer AG
    BeiGene Ltd
    Biovista Inc
    Blueprint Medicines Corp
    Boehringer Ingelheim GmbH
    Bristol-Myers Squibb Company
    Celldex Therapeutics Inc
    Centrose LLC
    Curis Inc
    Cytori Therapeutics Inc
    Daiichi Sankyo Company Ltd
    Ecrins Therapeutics SAS
    Eisai Co Ltd
    Ensol Biosciences Inc
    F. Hoffmann-La Roche Ltd
    Genelux Corp
    Genmab A/S
    GlaxoSmithKline Plc
    Gradalis Inc
    Hutchison MediPharma Ltd
    Ignyta Inc
    Immune Pharmaceuticals Inc
    Immunomedics Inc
    Johnson & Johnson
    Konruns Pharmaceutical Co Ltd
    Loxo Oncology Inc
    MacroGenics Inc
    MaxiVAX SA
    MedImmune LLC
    Merck & Co Inc
    Merck KGaA
    Millennium Pharmaceuticals Inc
    Nerviano Medical Sciences Srl
    Novartis AG
    Ono Pharmaceutical Co Ltd
    Pfizer Inc
    Plexxikon Inc
    Rodos BioTarget GmbH
    Synactix Pharmaceuticals Inc
    Tarveda Therapeutics Inc
    Vaccinex Inc
    Vascular Biogenics Ltd
    XSpray Microparticles AB

    Request for Sample

    Report Url http://www.reportsweb.com//thyroid-cancer-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//thyroid-cancer-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//thyroid-cancer-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments